NuCana shares are trading higher after the company announced final data from the Phase 2 NuTide:701 study at the ESMO Congress on NUC-7738 in combination with pembrolizumab for patients with metastatic melanoma who were refractory to or had relapsed on prior PD-1 inhibitor therapy.
Portfolio Pulse from Benzinga Newsdesk
NuCana's shares rose following the announcement of positive final data from their Phase 2 NuTide:701 study, presented at the ESMO Congress. The study involved NUC-7738 combined with pembrolizumab for treating metastatic melanoma in patients who were refractory to or had relapsed on prior PD-1 inhibitor therapy.
September 16, 2024 | 11:55 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
NuCana's stock price increased due to the positive final data from their Phase 2 study on NUC-7738, which was presented at the ESMO Congress. This study showed promising results for patients with metastatic melanoma.
The announcement of positive final data from a clinical study often leads to an increase in stock price, especially in the biotech sector. The study's success in treating a challenging condition like metastatic melanoma adds significant value to NuCana's portfolio, likely driving investor interest and confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100